Author/Authors :
Liang, Xinling Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Li, Ruizhao Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Zhang, Li Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Zhang, Shu Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Yang, Huan Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Yao, Bingfeng Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Dong, Wei Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Zhang, Bin Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Chen, Yuanhan Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Liu, Shuangxin Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Zhao, Xingchen Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Zhang, Qianmei Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China , Shi, Wei Division of Nephrology - Guangdong Provincial People’s Hospital - Guangdong Academy of Medical Sciences - Guangzhou, China
Abstract :
Increased glypican-5 expression in podocytes induces
podocyte injury. Glypican-5 is shed into the urine, but its value
in predicting progression of diabetic nephropathy (DN) has not
been investigated.
Methods. Glypican-5 was determined in spot urine from 20 type 2
diabetes mellitus (T2DM) patients, and 37 type 2 DN patients, and
20 healthy controls by enzyme-linked immunosorbent assay. The
association of urinary glypican-5 with markers of renal function
was evaluated.
Results. Urinary glypican-5 was significantly higher in DN patients
than in both DM patients and controls. Glypican-5 level was not
associated with baseline 24-hour urine protein/albumin excretion,
serum creatinine, estimated glomerular filtration rate (eGFR),
systolic blood pressure (SBP), or hemoglobin (Hb) A1c values in
the DN patients. After 52 weeks follow-up, urinary glypican-5
level was associated with significant increases in urine protein
and albumin excretion and a significant decline in eGFR in the
DN patients. The decline in eGFR was independent of changes in
urine protein and albumin excretion, SBP, or HbA1c. The results
indicate that urinary glypican-5 was not only a biomarker but also
contributed to the pathogenesis of DN in these patients.
Conclusion. Urinary glypican-5 was specifically elevated in type
2 diabetes patients with DN and it was associated with disease
progression. Urinary glypican-5 may serve as a useful non-invasive
marker for the progression of DN.
Keywords :
diabetic nephropathy , type 2 diabetes , estimated glomerular filtration rate , glypican-5, podocyte
